2024
Spectris™ treatment preserves corpus callosum structure in Alzheimer's disease
Da X, Hempel E, Brickman A, Hajós M, Kern R, Cimenser A. Spectris™ treatment preserves corpus callosum structure in Alzheimer's disease. Frontiers In Neurology 2024, 15: 1452930. PMID: 39479005, PMCID: PMC11522122, DOI: 10.3389/fneur.2024.1452930.Peer-Reviewed Original ResearchSafety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease
Hajós M, Boasso A, Hempel E, Shpokayte M, Konisky A, Seshagiri C, Fomenko V, Kwan K, Nicodemus-Johnson J, Hendrix S, Vaughan B, Kern R, Megerian J, Malchano Z. Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease. Frontiers In Neurology 2024, 15: 1343588. PMID: 38515445, PMCID: PMC10957179, DOI: 10.3389/fneur.2024.1343588.Peer-Reviewed Original ResearchAssessment of adverse eventsMild to moderate ADGamma oscillationsModerate ADAmyloid-related imaging abnormalitiesAlzheimer's diseaseMild-to-moderate Alzheimer's diseaseSecondary clinical outcome measuresTherapy systemPrimary outcome measureHigher adherence ratesWhole-brain volumeClinical outcome measuresSecondary outcome measuresModerate Alzheimer's diseaseDisease-modifying effectsBaseline MMSE scoreStudy discontinuationExperimental AD modelsWell-toleratedEfficacy outcomesClinical benefitAdverse eventsDaily treatmentClinical criteriaNoninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease
Da X, Hempel E, Ou Y, Rowe O, Malchano Z, Hajós M, Kern R, Megerian J, Cimenser A. Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease. Journal Of Alzheimer's Disease 2024, 97: 359-372. PMID: 38073386, PMCID: PMC10789351, DOI: 10.3233/jad-230506.Peer-Reviewed Original ResearchConceptsWhite matter atrophyActive treatment participantsMatter atrophyAlzheimer's diseaseMyelin lossTreatment participantsWhite matterNeuronal network functionT2-weighted MRIEarly disease interventionMRI outcomesClinical trialsEntorhinal regionWhite matter structuresHz stimulationMagnetic resonance imaging dataAfferent connectionsInclusion criteriaTherapeutic approachesAtrophySensory stimulationVolume assessmentDisease interventionDiseaseMyelin content
2023
Lobe‐specific changes in white matter volume and myelination following 6‐month 40 Hz gamma sensory stimulation in patients on the Alzheimer’s disease spectrum
Cimenser A, Da X, Hempel E, Malchano Z, Vaughan B, Megerian J, Hajos M. Lobe‐specific changes in white matter volume and myelination following 6‐month 40 Hz gamma sensory stimulation in patients on the Alzheimer’s disease spectrum. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.073143.Peer-Reviewed Original ResearchWhite matter volumeAlzheimer's diseaseWhite matterPlacebo groupTemporal lobeMatter volumeFrontal lobeParietal lobeWhite matter atrophyGray matter changesMRI T1 imagesTreatment group resultsMonth 3Month 6Neurological comorbiditiesT1w/T2w ratioMatter atrophyAD patientsMagnetic resonance imaging dataPathological changesOccipital lobePlacebo participantsMatter changesNeuronal activityTreatment groupsSensory‐Evoked 40Hz Gamma Oscillation: A Feasible and Promising Treatment Option for Alzheimer’s Disease
Hajos M, Boasso A, Cimenser A, Shpokayte M, Hempel E, Da X, Seshagiri C, Megerian J, Vaughan B, Malchano Z. Sensory‐Evoked 40Hz Gamma Oscillation: A Feasible and Promising Treatment Option for Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.072957.Peer-Reviewed Original ResearchClinical trialsAlzheimer's diseaseActive armPotential novel therapeutic interventionsSensory stimulationOccipital cortical thicknessAmyloid plaque loadAbnormal neuronal activityPivotal clinical trialsStimulation systemPromising treatment optionDifferent therapeutic approachesNovel therapeutic interventionsMinimal side effectsQuantitative MRI analysisNeuronal network oscillationsDaily therapyPlaque loadADCS-ADLBrain atrophyClinical presentationTreatment armsClinical benefitClinical efficacyAD pathologyDecay in Entorhinal White Matter/Gray Matter contrast in Alzheimer’s Disease Patients is reduced by 40Hz sensory stimulation
Da X, Hempel E, Malchano Z, Vaughan B, Megerian J, Hajos M, Cimenser A. Decay in Entorhinal White Matter/Gray Matter contrast in Alzheimer’s Disease Patients is reduced by 40Hz sensory stimulation. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.077337.Peer-Reviewed Original ResearchMagnetic resonance imagingEntorhinal regionAlzheimer's diseaseWhite matterPlacebo groupDisease patientsMRI measuresTreatment groupsPlacebo-controlled feasibility studyPhase I/IISensory stimulationMonth 6 visitMonths of treatmentStructural magnetic resonance imagingAlzheimer's disease patientsSignal intensityT1 magnetic resonance imagingLinear mixed-effects modelingMonth 3WM atrophyMyelin lossAD severityWM/GM contrastMixed-effects modelingAD patients
2022
Coherent Activity in EEG Response to Gamma Sensory Stimulation Predicts Positive Outcome in Cognitive and Functional Abilities, and Brain Atrophy in Subjects with Alzheimer’s Disease (P4-6.004)
Cimenser A, Mrozak H, Da X, Travers T, Hempel E, Seshagiri C, Boasso A, Vaughan B, Megerian J, Malchano Z, Hajos M. Coherent Activity in EEG Response to Gamma Sensory Stimulation Predicts Positive Outcome in Cognitive and Functional Abilities, and Brain Atrophy in Subjects with Alzheimer’s Disease (P4-6.004). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1799.Peer-Reviewed Original ResearchFeasibility, Safety, and Efficacy of Gamma Sensory Stimulation as a Novel Therapeutic Intervention for Alzheimer’s Disease (N1.001)
Megerian J, Hajos M, Hempel E, Cimenser A, Boasso A, Cotter C, Williams M, Kwan K, Nicodemus-Johnson J, Hendrix S, Vaughan B, Malchano Z. Feasibility, Safety, and Efficacy of Gamma Sensory Stimulation as a Novel Therapeutic Intervention for Alzheimer’s Disease (N1.001). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1936.Peer-Reviewed Original Research